Orthopedic Surgery Malpractice Insurance in New York: A 2026 Surgeon's Guide

TL;DR. New York and Florida lead the nation in orthopedic malpractice premium, with Manhattan benchmarks at ~$125K and Long Island slightly above at $1M/$3M claims-made limits. Sub-specialty relativities stack on the base (spine ~1.3–1.5x, sports medicine ~1.1x, hand below base), tail runs roughly 150–200% of final annual premium, and MLMIC, EmPRO, The Doctors Company, and MedPro compete for most private-practice surgeons.

NY orthopedic private practice density

New York and Florida consistently rank as the two highest-premium orthopedic malpractice markets in the United States, driven by no damage caps on non-economic harm and a dense plaintiff's bar concentrated in NYC and Long Island (American Academy of Orthopaedic Surgeons, 2024). New York carries roughly 5,100 licensed orthopedic surgeons across private practice, academic medicine, and hospital-employed models, with rate profiles that diverge sharply based on employment structure and sub-specialty scope.

Private practice versus hospital-employed claim profile

The claim profile for NY orthopedic surgeons differs measurably by employment model. Private-practice surgeons, particularly those with ownership stakes in ambulatory surgical centers or specialty hospitals, absorb both the clinical and the entity-level malpractice exposure. Hospital-employed surgeons typically sit under a master policy or a captive structure that narrows the surgeon's personal liability window to the scope of their employed duties, though individual reporting obligations to the National Practitioner Data Bank remain identical.

The underwriting implication is practical. A Manhattan private-practice orthopedic surgeon running a shared-ownership ASC pays for the surgeon's clinical risk, the entity's premises and vicarious exposure, and the ASC's separate policy. A hospital-employed peer at a Columbia or NYU affiliate pays only the personal-scope portion, with the hospital absorbing the institutional layer. This is why two surgeons doing the same work can quote at very different all-in numbers.

Where NY orthopedic surgeons concentrate

Roughly 60% of NY orthopedic surgeons practice in the downstate zones of Manhattan, Brooklyn, Queens, the Bronx, Nassau, Suffolk, and Westchester. The remaining 40% are distributed across the Capital Region, the Mid-Hudson Valley, Rochester, Buffalo, Syracuse, and smaller regional networks. Private-practice concentration is highest in Nassau and Suffolk counties, where multi-surgeon orthopedic groups and ASC ownership are the dominant model.

Upstate concentrations cluster around academic medical centers in Rochester (University of Rochester) and Buffalo (UB Jacobs School). In those markets, hospital employment dominates private practice by a wide margin, which shifts the rate profile toward the institutional structure described above. The practical effect on an individual surgeon's personal premium is a 50–70% reduction compared to a downstate private-practice peer, before any sub-specialty relativity.

Why employment structure matters at renewal

At each annual renewal, NY orthopedic surgeons should confirm how their current employment structure interacts with their policy form. A surgeon moving from hospital employment into private practice mid-career often needs a new policy with its own retroactive date, separate tail on the departing employer's master policy, and a sub-specialty relativity that the institutional policy may not have itemized. Missing any of these at the transition creates coverage gaps that can take years to surface and cost six figures to remediate.

Across NY orthopedic placements, we see roughly one in four surgeons change employment models without written confirmation of retro continuity, tail responsibility, or scope-of-practice documentation. Each of those three items deserves a written confirmation from the relevant carrier or employer before the transition date, not after.

What are the sub-specialty carve-outs and relativities?

Carriers apply sub-specialty relativities on top of the base orthopedic rate, producing meaningful price differentiation across fellowship-trained subspecialties. Spine surgery typically carries a 1.3–1.5x relativity, sports medicine ~1.1x, total joint ~1.0x, pediatric orthopedics near 1.0x, foot and ankle roughly 0.95x, and hand/upper extremity often 0.85–0.9x (MedPro Group rate filings summary, 2024). The relativity reflects historical claim severity rather than fellowship credentials alone, and carriers rate the actual scope performed.

Spine surgery (1.3–1.5x)

Spine surgery carries the highest sub-specialty relativity in the NY orthopedic book because the clinical failure modes, including nerve-root damage, cauda equina, and paralysis, produce the largest paid-claim values in the specialty. MLMIC, EmPRO, and TDC all apply a roughly 1.3–1.5x factor on top of base ortho for surgeons whose scope includes discectomy, laminectomy, spinal fusion, or deformity correction.

Cervical spine cases price at the upper end of the relativity range because verdict severity for cervical cord injury tends to exceed lumbar. Deformity and scoliosis correction adds additional scrutiny in underwriting. A Manhattan spine surgeon at the base ortho ~$125K benchmark can see an all-in quote near $165K to $190K after the relativity lands.

Sports medicine (1.1x)

Sports medicine sits modestly above base ortho at roughly 1.1x. The profile reflects high-volume arthroscopic work on knees, shoulders, and hips, which produces frequent but lower-severity claims compared to spine. The sub-specialty often interacts with team-physician contracts for collegiate and professional sports programs, and those contracts typically require named-insured endorsements that carriers add without changing the base relativity.

A sports medicine surgeon handling collegiate or professional team coverage in NY should confirm that the team's medical services contract names primary coverage to the surgeon's carrier, not the institution. The vicarious-liability analysis can shift financial exposure in ways that only surface once a claim is filed.

Total joint and foot/ankle

Total joint replacement (hip, knee, shoulder) prices near the base ortho relativity of 1.0x. The specialty has a well-documented risk profile, implant-related litigation is typically pursued against the device manufacturer rather than the surgeon, and carriers price accordingly. Foot and ankle, which overlaps with podiatric scope at some institutions, often lands at 0.95x because the claim-severity distribution is narrower.

Revision arthroplasty, which is a distinct scope from primary joint replacement, carries a slightly higher relativity at some carriers due to the infection and implant-failure complexity. A surgeon whose practice mix includes material revision volume should confirm the carrier's scope classification at application and each renewal.

Hand/upper extremity (0.85–0.9x)

Hand and upper-extremity surgery typically prices below base ortho, in the 0.85–0.9x range. The claim-severity distribution is narrower than for spine or total joint, and the scope is often office-based or ambulatory rather than inpatient. For a hand surgeon in Manhattan, the relativity discount can move the annual premium from the ~$125K base benchmark down toward the ~$105K–$115K range before any credits.

Carriers that separately rate hand scope often require the surgeon's CPT-code mix at application, and a practice dominated by hand and upper-extremity work qualifies for the discount only when that mix is documented. A general orthopedic practice with occasional hand cases does not qualify.

Pediatric orthopedics

Pediatric orthopedics at NY admitted carriers prices at roughly 1.0x base, with the caveat that minors tolling under NY law extends the reporting window materially. A claim arising from pediatric orthopedic care can be filed up to 10 years after the alleged negligence, or 2.5 years after the child turns 18, whichever is earlier. Carriers reserve pediatric ortho long-tail claims accordingly, even when the nominal relativity does not mark the specialty up.

Surgeons whose pediatric volume includes complex deformity, tumor, or neuromuscular work should confirm that the carrier's pediatric-specific sub-code covers the scope performed. A general-pediatric code applied to a deformity-correction practice creates a coverage mismatch that surfaces only when a claim is contested.

NY orthopedic cost table by zone

New York and Florida rank first and second nationally for orthopedic malpractice premium, with Manhattan benchmarks at $1M/$3M claims-made limits near ~$125K and Long Island typically pricing slightly above that figure (NAIC Medical Professional Liability Report, 2024). Upstate zones discount 50–70% against the downstate base, producing a 3–4× spread on the same specialty code within the state.

Zone-by-zone premium ranges

Why Long Island prices above Manhattan

Long Island's Nassau and Suffolk county zone carries the state's highest territory modifier for orthopedic surgery, higher even than Manhattan. The driver is jury-verdict history, specifically the concentration of nuclear verdicts in Nassau County Supreme Court over the past decade. Manhattan's verdict distribution is broader but more moderated, producing a lower average severity per paid claim despite higher total dollars. For a surgeon deciding between a Great Neck practice and a Manhattan practice, the premium delta alone can exceed $15,000–$25,000 annually on base ortho, before any sub-specialty relativity.

Upstate discount zones

Rochester, Syracuse, Buffalo, and the Southern Tier all sit at territory factors of roughly 0.3–0.5 relative to the downstate base. For orthopedic surgery, that translates to an annual premium in the $35K–$52K range at $1M/$3M claims-made limits, compared to the $125K Manhattan benchmark. The dollar savings compound across a career because tail at retirement is priced off the final annual premium, which means the upstate discount persists into the retirement buyout. Over a 20-year career, the lifetime coverage cost difference between a Rochester and a Manhattan spine surgeon can reach $2M to $3M.

Published rate filings versus actual paid premium

Published filings on the NY Department of Financial Services rate database resolve to zones but not to the full carrier-specific modifier stack. A surgeon benchmarking premium against published tables will understate the variance between carriers in a downstate zone by 10–20% in most cases. A multi-carrier quote comparison, not a single published rate, is what produces a realistic view of actual paid premium. The ranges in the zone table reflect broker-observed quotes across MLMIC, EmPRO, TDC, and MedPro for mid-career surgeons at standard limits.

How do NY orthopedic carriers compare?

Five carriers write most NY orthopedic malpractice policies: MLMIC (now a Berkshire Hathaway subsidiary), The Doctors Company (TDC), MedPro Group (a Berkshire Hathaway subsidiary), Coverys, and CNA through specialty programs (NAIC market share data, 2024). Each carrier brings a distinct underwriting philosophy, territory grid, and sub-specialty appetite. A multi-carrier quote is the only reliable way to identify the competitive placement for a given surgeon.

MLMIC

Medical Liability Mutual Insurance Company is NY's largest medical professional liability writer and has held that position for more than 45 years. It insures over 13,000 physicians and 3,000 dentists across the state (MLMIC, 2024). MLMIC's orthopedic appetite is broad, covering private practice, hospital-employed, and ASC-affiliated surgeons at standard and excess limits. Its territory grid consolidates Brooklyn and Queens at a single downstate factor, which can disadvantage Queens surgeons relative to carriers with more granular grids.

The MLMIC dividend question, driven by the 2018 Berkshire Hathaway acquisition and the CBMS line of cases, remains a live issue for many orthopedic surgeons who were employed at the time of the demutualization. Surgeons who believe they may have unclaimed dividend or distribution interests should consult counsel before the contract-based limitation period runs.

The Doctors Company (TDC)

The Doctors Company is a physician-owned national mutual and the largest MPL writer in the United States by policyholder count. In New York, TDC's book skews toward employed orthopedic surgeons at hospital-affiliated groups and multi-state practices, because TDC can write consistent limits across state lines where MLMIC is NY-only. TDC's dividend history is a practical consideration for long-horizon surgeons; the carrier has paid dividends in most recent years to eligible policyholder groups.

TDC's territory factor for downstate NY often produces the most competitive Manhattan quote for multi-state orthopedic groups. The trade-off is that TDC's claim handling follows a national model that some NY surgeons find less locally calibrated than MLMIC's in-state claim defense network.

MedPro Group

MedPro is the other Berkshire Hathaway-owned MPL carrier and writes a meaningful share of NY orthopedic surgeons, particularly in sub-specialty segments. MedPro's underwriting for spine surgery and complex revision arthroplasty is often more flexible than the NY-only carriers, and the carrier's rate filings reflect a national actuarial base adjusted for NY filings. For high-severity sub-specialties or surgeons with a recent claim in their history, MedPro quotes are worth pulling in parallel with MLMIC and TDC.

Claim defense at MedPro uses a national panel of law firms, with NY-specific defense counsel engaged on a case-by-case basis. Surgeons who value a pre-established relationship with NY defense counsel may prefer MLMIC's in-state panel; those who value underwriting flexibility often prefer MedPro.

Coverys and CNA programs

Coverys (formerly ProMutual) writes NY orthopedic business primarily through its specialty underwriting units, with a book that emphasizes academic medical centers and large multi-specialty groups. CNA participates in NY orthopedic placements through specialty programs rather than direct admitted filings, which means the CNA path is typically accessed through a broker-administered program rather than a retail quote.

Both carriers tend to price competitively for clean-history surgeons in downstate zones but have narrower appetite for sub-specialty scope or recent paid-claim histories. For surgeons with a straightforward profile, either carrier is a reasonable inclusion in a multi-carrier quote comparison; for surgeons with complexity, MLMIC, TDC, and MedPro typically produce the most actionable quotes.

Why multi-carrier quotes matter

Two brokers quoting the same NY orthopedic surgeon in the same zip code can produce quotes that differ by 20% or more, not because either is wrong but because each carrier's territory grid, sub-specialty appetite, and credit structure respond differently to the same inputs. The surgeon who takes the first quote typically leaves meaningful premium on the table. A comparison across MLMIC, TDC, MedPro, and one of Coverys or CNA, priced at identical limits and deductibles, is the minimum baseline for a competitive placement.

What limits should a NY orthopedic surgeon carry?

Most NY orthopedic surgeons carry primary limits of $1M/$3M with an excess layer of $1M to $5M stacked on top, reflecting a combination of hospital bylaw requirements, personal asset protection, and nuclear-verdict exposure (NY Department of Financial Services, 2026 filings reference). Manhattan teaching hospitals typically require $1M/$3M at minimum for credentialed ortho staff, with many mandating $2M/$4M or $2M/$6M for high-risk sub-specialties.

The $1M/$3M primary floor

$1M per claim and $3M annual aggregate is the de facto minimum for NY orthopedic surgeons, set by a combination of carrier filing conventions and hospital credentialing requirements. The $1M limit is the rating basis for most of the figures discussed in this guide. Dropping below $1M/$3M is possible in a handful of low-scope scenarios but is rare in practice and usually fails credentialing review at a NY hospital.

The $3M annual aggregate allows up to three full-limit claims in a single policy year before coverage exhausts. For orthopedic surgery, claim frequency tends to run below the aggregate threshold for most surgeons in most years, but the aggregate matters for high-volume practices and for surgeons with a recent cluster of claims.

Why NY orthopedic surgeons typically buy above the floor

Nuclear verdicts in NY, including recent awards exceeding $100M in medical malpractice cases, create real exposure above the $1M primary limit. A $2M or $3M excess layer, priced at roughly 10–20% of the primary premium, closes the gap between the primary limit and a plausible severe-verdict outcome. For spine, complex revision, and pediatric deformity practices, many surgeons carry $5M or more in excess above the primary.

The credentialing requirement at NYC teaching hospitals frequently pushes surgeons above the basic floor. Residency programs and medical staff offices at Columbia, NYU, Mount Sinai, Cornell, and Montefiore publish minimum-limit requirements that often exceed $1M/$3M for ortho staff, particularly in spine and complex trauma sections. Confirm the specific limit requirement against the hospital's current credentialing packet before binding a new policy.

How excess layers stack

Excess layers sit above the primary policy and respond only when the primary limit is exhausted. Pricing runs at roughly 10% of the primary premium for a $1M excess layer and scales upward non-linearly to 25–35% for $5M excess limits. The excess carrier's appetite often determines the economics: some carriers have aggressive NY appetite and competitive excess pricing, while others decline or price prohibitively.

A common NY structure is $1M/$3M primary from MLMIC or TDC, $2M/$4M first excess from a specialty carrier, and $2M additional excess from a second carrier. The stacking produces a $5M/$7M total limit at a cost that usually runs 25–35% above the primary alone. Surgeons negotiating a new employment contract should confirm whether the employer funds the excess layer or whether it falls on the physician.

Section 18 Excess context

New York's Section 18 Excess Medical Malpractice Program historically provided a state-funded $1M/$3M layer above a physician's primary $1.3M/$3.9M limit at no cost to eligible physicians. Multiple broker advisories report that the program closed to new enrollment on December 31, 2024, with existing enrollees grandfathered. Physicians who relied on Section 18 for credentialing limits now need broker-sourced excess at their own cost, and the market has not yet absorbed the full substitution demand. No NY Department of Health primary source confirming the closure has been located, so surgeons should verify current status before making coverage decisions.

What does tail cost and when should you buy it?

Tail coverage, technically an extended reporting endorsement, typically costs 150–200% of the most recent annual claims-made premium, paid as a single lump sum at policy termination. For a Manhattan orthopedic surgeon at the ~$125K base benchmark, that translates to a $190K–$250K one-time check at retirement, job change, or specialty shift. The multiplier exists because the carrier must reserve for the entire long-tail reporting window with no future premium stream.

The 200% ceiling and its actual range

Industry-standard tail modeling uses a flat 200% multiplier, and that is the right ceiling to assume when planning. In actual NY orthopedic quotes, the multiplier runs from about 150% for lower-severity sub-specialties with shorter reporting development, up to the full 200% or slightly above for spine and complex revision work. The span reflects each sub-specialty's historical claim-development curve: claims that take longer to surface carry more uncertainty, and carriers price that uncertainty into the tail factor.

For a surgeon whose practice mix changes materially in the final years, the tail factor at exit reflects the most recent scope, not the full career average. A spine surgeon who winds down to general orthopedic work in the final two years before retirement often sees the tail priced against the lower-scope rate, which can save a meaningful share of the buyout.

Free-tail triggers

The free-tail provision waives tail cost when termination follows specific triggers. Standard triggers include retirement at age 55 or older with at least five years of continuous coverage, total permanent disability, or death. Some carriers extend the retirement trigger to age 50 after ten years of continuous coverage, and a handful offer a graduated free-tail structure that vests incrementally after three years of coverage.

Surgeons negotiating a new employment contract should push for a free-tail trigger on retirement and disability at minimum, because those are the two termination modes hardest to predict and most expensive to self-fund. A free-tail provision is worth six figures on a Manhattan orthopedic book and often more on Long Island.

Lifetime versus shorter-term tail

Tail coverage is typically purchased as lifetime (unlimited reporting period) rather than as a shorter-term endorsement. The lifetime structure reflects NY's long-tail statutory framework: Lavern's Law extends cancer-misdiagnosis reporting windows to seven years from the alleged negligence, and minors tolling for pediatric orthopedics can extend reporting up to ten years. A shorter-term tail, such as three or five years, can leave coverage gaps if claims surface outside the purchased window.

The exception is a surgeon who plans to re-enter practice after a sabbatical or relocation. In that case, the nose coverage on the new carrier can substitute for the departing carrier's tail, and the economics of a shorter-term tail versus full lifetime become situational. For permanent career exits, lifetime tail is the prevailing standard.

Career-exit timing

Because tail is priced off the most recent annual premium, surgeons approaching retirement can reduce the bill by stepping down scope in the final year. A spine surgeon winding down to general orthopedic work in year one of a two-year retirement transition may see annual premium fall by 25–35%, which proportionally lowers the tail. The arithmetic has to account for the year's premium and the tail together, because the carrier's final step rating applies in parallel, but for many surgeons the scope reduction saves a meaningful share of the tail bill. The strategy only works with advance planning and an explicit carrier conversation about credential and scope documentation.

For deeper specialty-specific context on the analyses above, review our companion guides on NY medical malpractice insurance fundamentals for physicians, OB/GYN malpractice pricing across NY, and general surgery malpractice rates in New York. Readers weighing career exits or carrier switches should see our detailed treatment of when tail coverage is required and how to price it and the structural comparison of occurrence and claims-made policies in NY. A case study of the real cost of a $2M malpractice verdict on a NY physician illustrates how primary and excess limits interact when a verdict exceeds the primary. Service-level information lives on the professional liability coverage page and industry context sits on the physicians industry page.

NY orthopedic surgeons with a renewal inside the next 90 days, a carrier switch on the table, or a new employment contract under review benefit most from a multi-carrier quote comparison across MLMIC, TDC, MedPro, and one of Coverys or CNA at identical limits. A 30-minute conversation with a broker appointed across those carriers is typically the most valuable hour in the placement process. You can request a quote or schedule a consultation when you are ready.